CAR T 细胞疗法耐药机制。
Mechanisms of resistance to CAR T cell therapies.
机构信息
Division of Oncology, Section of Stem Cell Biology, Washington University School of Medicine, St. Louis, MO, 63105, United States.
Novartis Institutes for Biomedical Research, Cambridge, MA, 02139, United States.
出版信息
Semin Cancer Biol. 2020 Oct;65:91-98. doi: 10.1016/j.semcancer.2019.12.002. Epub 2019 Dec 19.
Abstract
Chimeric antigen receptor (CAR)-engineered T cells have demonstrated remarkable success in the treatment of B cell malignancies. FDA approval of these therapies represents a watershed moment in the development of therapies for cancer. Despite the successes of the last decade, many patients will unfortunately not experience durable responses to CAR therapy. Emerging research has shed light on the biology responsible for these failures, and further highlighted the hurdles to broader success. Here, we review the recent research identifying how interactions between cancer cells and engineered immune cells result in resistance to CAR therapies.
摘要
嵌合抗原受体 (CAR)-修饰的 T 细胞在治疗 B 细胞恶性肿瘤方面取得了显著的成功。这些疗法获得 FDA 的批准代表了癌症治疗发展的一个重要时刻。尽管过去十年取得了成功，但不幸的是，许多患者不会对 CAR 疗法产生持久的反应。新出现的研究揭示了导致这些失败的生物学机制，并进一步强调了取得更广泛成功的障碍。在这里，我们回顾了最近的研究，这些研究确定了癌细胞与工程免疫细胞之间的相互作用如何导致对 CAR 疗法的耐药性。
相似文献
1
Mechanisms of resistance to CAR T cell therapies.CAR T 细胞疗法耐药机制。
Semin Cancer Biol. 2020 Oct;65:91-98. doi: 10.1016/j.semcancer.2019.12.002. Epub 2019 Dec 19.
2
Determinants of response and resistance to CAR T cell therapy.嵌合抗原受体 T 细胞疗法的反应和耐药的决定因素。
Semin Cancer Biol. 2020 Oct;65:80-90. doi: 10.1016/j.semcancer.2019.11.004. Epub 2019 Nov 6.
3
Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.嵌合抗原受体修饰 T 细胞免疫治疗：一种新型细胞治疗方法，对临床实验室具有重要意义。
Clin Chem. 2019 Apr;65(4):519-529. doi: 10.1373/clinchem.2016.258988. Epub 2018 Dec 28.
4
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤：疗效、毒性和比较嵌合抗原受体产品。
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
5
Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.嵌合抗原受体 T 细胞疗法在实体瘤治疗中的进展。
Clin Pharmacol Ther. 2019 Jan;105(1):71-78. doi: 10.1002/cpt.1280.
6
Generation of CAR-T Cells for Cancer Immunotherapy.用于癌症免疫治疗的嵌合抗原受体T细胞的生成。
Methods Mol Biol. 2019;1884:349-360. doi: 10.1007/978-1-4939-8885-3_24.
7
Therapeutic potential of CAR T cell in malignancies: A scoping review.嵌合抗原受体T细胞在恶性肿瘤中的治疗潜力：一项范围综述。
Biomed Pharmacother. 2022 Feb;146:112512. doi: 10.1016/j.biopha.2021.112512. Epub 2021 Dec 9.
8
T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.基于 T 细胞的血液系统恶性肿瘤免疫疗法，B 部分：过继细胞疗法的 SWOT 分析。
Anticancer Res. 2021 Mar;41(3):1143-1156. doi: 10.21873/anticanres.14871.
9
Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.嵌合抗原受体 (CAR) T 细胞治疗的进展：现状与展望。
Arch Pharm Res. 2019 Jul;42(7):607-616. doi: 10.1007/s12272-019-01136-x. Epub 2019 Mar 4.
10
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.肝细胞癌治疗中药物治疗、免疫治疗和 CAR-T 细胞治疗的新见解。
Drug Resist Updat. 2020 Jul;51:100702. doi: 10.1016/j.drup.2020.100702. Epub 2020 Apr 19.
引用本文的文献
1
Atypical lymphoid proliferations associated with therapeutic intervention: a report of the 2024 EA4HP/SH lymphoma workshop.与治疗干预相关的非典型淋巴样增殖：2024年EA4HP/SH淋巴瘤研讨会报告
Virchows Arch. 2025 Aug 13. doi: 10.1007/s00428-025-04197-0.
2
Immune mediated inflammatory diseases: moving from targeted biologic therapy, stem cell therapy to targeted cell therapy.免疫介导的炎症性疾病：从靶向生物疗法、干细胞疗法到靶向细胞疗法。
Front Immunol. 2025 Apr 7;16:1520063. doi: 10.3389/fimmu.2025.1520063. eCollection 2025.
3
AAV-mediated co-expression of an immunogenic transgene plus PD-L1 enables sustained expression through immunological evasion.腺相关病毒介导的免疫原性转基因与 PD-L1 的共表达通过免疫逃逸实现持续表达。
Sci Rep. 2024 Nov 21;14(1):28853. doi: 10.1038/s41598-024-75698-2.
4
Complete loss of lineage defining antigens in two cases of B-cell malignancies following CAR-T therapy.两例B细胞恶性肿瘤患者接受嵌合抗原受体T细胞（CAR-T）治疗后谱系定义抗原完全丧失。
J Hematop. 2024 Dec;17(4):259-264. doi: 10.1007/s12308-024-00602-w. Epub 2024 Aug 26.
5
GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.靶向 GPC3 的 CAR-T 细胞表达 GLUT1 或 AGK 可增强对肝细胞癌的抗肿瘤活性。
Acta Pharmacol Sin. 2024 Sep;45(9):1937-1950. doi: 10.1038/s41401-024-01287-8. Epub 2024 May 15.
6
Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data.嵌合抗原受体T细胞疗法治疗中枢神经系统淋巴瘤的持续疗效：个体数据的系统评价和荟萃分析
Front Pharmacol. 2024 Jan 24;14:1331844. doi: 10.3389/fphar.2023.1331844. eCollection 2023.
7
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.塔法西单抗与 CD19 结合增加了 CART19 细胞疗法的治疗指数，并降低了 CRS 的严重程度。
Blood. 2024 Jan 18;143(3):258-271. doi: 10.1182/blood.2022018905.
8
Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead.嵌合抗原受体 T 细胞疗法治疗成人 B 细胞急性淋巴细胞白血病：现状与未来展望。
Blood Adv. 2023 Jul 25;7(14):3350-3360. doi: 10.1182/bloodadvances.2022009462.
9
Advances in adoptive cellular therapy for colorectal cancer: a narrative review.结直肠癌过继性细胞治疗的进展：一项叙述性综述
Ann Transl Med. 2022 Dec;10(24):1404. doi: 10.21037/atm-22-6196.
10
Clutch Control: Changing the Speed and Direction of CAR-T Cell Therapy.精准控制：改变CAR-T细胞疗法的速度与方向
J Cancer Immunol (Wilmington). 2022;4(2):52-59.
本文引用的文献
1
Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.嵌合抗原受体修饰的慢病毒转导 T 细胞识别间皮素治疗晚期实体瘤的 I 期临床研究。
Mol Ther. 2019 Nov 6;27(11):1919-1929. doi: 10.1016/j.ymthe.2019.07.015. Epub 2019 Jul 30.
2
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.酪氨酸激酶抑制剂 dasatinib 可作为 CAR T 细胞的药理学开/关开关。
Sci Transl Med. 2019 Jul 3;11(499). doi: 10.1126/scitranslmed.aau5907.
3
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.嵌合抗原受体 T 细胞疗法治疗复发性或难治性成人弥漫性大 B 细胞淋巴瘤的成本效果分析。
J Clin Oncol. 2019 Aug 20;37(24):2105-2119. doi: 10.1200/JCO.18.02079. Epub 2019 Jun 3.
4
HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA liver metastases.HITM-SIR：CEA 肝转移的动脉内嵌合抗原受体 T 细胞治疗和选择性内放射治疗的 Ib 期试验。
Cancer Gene Ther. 2020 May;27(5):341-355. doi: 10.1038/s41417-019-0104-z. Epub 2019 Jun 3.
5
Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.双表位 CAR T 靶向 B 细胞成熟抗原治疗复发/难治性多发性骨髓瘤的探索性试验。
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551. doi: 10.1073/pnas.1819745116. Epub 2019 Apr 15.
6
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape.嵌合抗原受体 T 细胞 trogocytosis 和协同杀伤调节肿瘤抗原逃逸。
Nature. 2019 Apr;568(7750):112-116. doi: 10.1038/s41586-019-1054-1. Epub 2019 Mar 27.
7
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.B 细胞成熟抗原特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中具有临床活性。
J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
8
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.新辅助抗 PD-1 免疫治疗在复发性胶质母细胞瘤中促进了肿瘤内和全身免疫应答，并带来生存获益。
Nat Med. 2019 Mar;25(3):477-486. doi: 10.1038/s41591-018-0337-7. Epub 2019 Feb 11.
9
Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers.幼稚 T 细胞缺陷在诊断时和化疗后损害儿科癌症的细胞治疗潜能。
Cancer Discov. 2019 Apr;9(4):492-499. doi: 10.1158/2159-8290.CD-18-1314. Epub 2019 Jan 10.
10
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.靶向CD19和CD22的双价嵌合抗原受体的临床前开发
Mol Ther Oncolytics. 2018 Nov 6;11:127-137. doi: 10.1016/j.omto.2018.10.006. eCollection 2018 Dec 21.
Zotero 插件